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Background: The relationship between Type 2 diabetes mellitus (T2DM) and associated co-morbidities, particularly major
depressive disorder (MDD), is poorly acknowledged in chronic disease management practices in South Africa. Managed
healthcare costs and hospitalisation rates may be influenced by the discrete management of co-morbid conditions.
Therefore, the relationship between T2DM and MDD in terms of co-morbidity incidence and hospitalisation resource
utilisation was investigated.
Method: This retrospective descriptive study analysed the data of 902 adult patients with T2DM from the health system
database of a private managed healthcare organisation for 2014.
Results: The mean age was 57 ± 15 years and 85% of the identified T2DM patients had at least one recorded co-morbidity.
Among this population 17% presented with MDD. A higher percentage of T2DM patients with MDD were admitted to
hospital (42%, p = 0.004) compared with those without MDD (30%). The number of overnight admissions was higher among
the T2DM with MDD (76%, p = 0.016) compared with T2DM without MDD (66%). The T2DM with MDD group (85%, p = 0.018)
had greater non-diabetes related hospital events compared with the T2DM without MDD group (73%). The T2DM patients
without MDD were more likely to be hospitalised for diabetes-related events (27%, p = 0.018) at significantly higher
admission cost (p = 0.001).
Conclusion: Patients with T2DM and MDD present with more co-morbid conditions and had a higher number of hospitalisations
than their non-MDD counterparts. However, the hospitalisation costs were significantly higher for diabetes-related admissions in
the non-MDD group due to a higher number of macrovascular events. Healthcare organisations need to focus on an integrated
approach in the management of chronic conditions with emphasis on active surveillance of T2DM patients, where MDD is
identified and treated to lessen the risk of macrovascular complications.
Keywords: concordant and discordant co-morbidities, hospital utilisation, major depressive disorder (MDD), Type 2 diabetes
mellitus (T2DM)
Introduction
Type 2 diabetes mellitus (T2DM) and major depressive disorder
(MDD) are major public health problems affecting vast numbers
of individuals worldwide. Based on the 2015 International Dia-
betes Federation (IDF) estimates for South Africa (SA), there
were 2.3 million adults (aged 20–79 years) with diabetes; the
national prevalence was 7.0% with a comparative world preva-
lence of 7.6%.1 T2DM and its complications are a concerning
source of mortality and a heightened healthcare burden in
sub-Saharan Africa.2 Many studies have discussed the healthcare
utilisation and costs of T2DM patients with microvascular and
macrovascular complications.3 Developing and established
economies such as Asia, Russia, Canada, the UK, Germany and
Australia show that hospitalisation costs associated with major
coronary artery disease (CAD), cerebrovascular disease and
heart failure is significantly higher than hospitalisations for
non-major cardiovascular outcomes.4
Co-morbidities frequently occur in patients with T2DM.5
Approximately 80% of T2DM patients have at least one
additional co-morbid condition creating further pressure on
the patient and healthcare system.6 Conditions that are co-
morbid with T2DM such as coronary artery and cerebrovascular
diseases are often referred to as concordant co-morbidities (CC),
due to the similarity of pathogenesis and management. Discor-
dant co-morbidities (DC) such as MDD, cancer and rheumatoid
arthritis are considered discrete conditions to T2DM but may
co-occur.7 The 2009 prevalence data indicated that 9.7% of
South Africans would have an MDD episode in their lifetime.8
In the South African private managed healthcare arena the DC,
such as patients with both T2DM and MDD, are managed indivi-
dually through standardised protocols and guidelines per
condition.9,10
Traditionally, the focus of managed healthcare models for T2DM
is the prevention of hospitalisations due to hypoglycaemia or
diabetic ketoacidosis.11–13 These models overlook the other
aspects in diabetes management such as cardiovascular
disease (CVD), yet many studies have demonstrated the benefits
of targeting CVD risk factors such as hypertension and hyperlipi-
daemia in T2DM patients.14,15 As many as 50% of T2DM patients
die of a CVD event such as CAD, which is a major macrovascular
complication of T2DM.16,17
Few studies have focused on mood disorders in patients with
T2DM, yet these patients are affected by MDD nearly twice as
much as in the general population.18 MDD has been identified
as an independent risk factor for both the development of
CAD and for worsening prognosis once CAD is established.19
In an observational secondary analysis report of patients with
CAD, the identification and treatment of MDD showed a 43%
reduction of recurrent myocardial infarction.20 Enhanced
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depression care for patients with acute coronary syndrome and
persistent depressive symptoms has shown promising reduction
in the rates of major adverse cardiac events.21 Therefore, we
investigated the relationship between the stated diagnoses of
T2DM and MDD, within a private managed healthcare setting,




The paper presents a retrospective descriptive study of the 2014
healthcare data of 902 adult T2DM patients in a private
managed healthcare database of a Chartered Accountants (SA)
Medical Aid Fund (CAMAF). Data were sourced from the iMed
database, a commercially available administrative system that
maintains membership data, claims processing and premiums
of members of private medical aid organisations such as the
patients with T2DM and/or MDD within CAMAF. The database
included:
. patient-level demographics and periods of health plan
enrolment;
. medicine management and prescription drug use;
. programme member registration;
. primary and non-primary International Classification of Dis-
eases and Related Health Problems, 10th revision (ICD10)
diagnosis codes;22
. detailed information regarding hospitalisations, diagnostic
testing and therapeutic procedures;
. inpatient and outpatient physician and auxiliary services;
. cost data in the form of managed-care reimbursement
rates for each service.
Confidentiality was maintained throughout the analysis; the
patients’ unique CAMAF membership number and dependent
code were used to align patient records.
Setting
The data for this study was obtained at Sanlam Health, a private
managed healthcare organisation. Sanlam Health is contracted
out to private medical aid bodies such as CAMAF to deliver
healthcare services. The study was approved by the University
of the Witwatersrand Johannesburg, Faculty of Health Sciences
Human Ethics Committee (M140326). Approval was also
granted by the Principal Officer of CAMAF for the CAMAF data
to be used in the study and by the Human Resources Manager
of Sanlam Health to gather data from the iMed database for
the research.
Patients
Patients were classified as having T2DM if they had any of the
ICD10 diagnosis codes of E11.0 to E11.9 and E12.0 to E12.9 as
stated by the practitioner and identified to be on insulin accord-
ing to the Anatomical Therapeutic Chemical Classification of
A10A (‘Insulin and analogues’). Patients diagnosed with MDD
were identified with ICD10 codes F32.2, F32.3, F32.8, F32.9,
F33.1, F33.2, F33.3, F33.4, F33.8, and F33.9. The ICD10 codes uti-
lised in this study were obtained from the Council of Medical
Schemes Prescribed Minimum Benefit CMS PMB ICD-10 coded
list 2013.23
Patients were included in the sample if they were registered on a
medicine management programme for T2DM, MDD and other
co-morbid conditions in 2014. The disease management pro-
grammes target registered patients’ disease control in terms of
medicines compliance, lifestyle changes and side effects on
their medication. Advice is offered on the importance of
doctor’ visits, performing annual lipograms, blood pressure
(BP) monitoring and smoking cessation.
Patients were grouped by their types of co-morbidities as out-
lined by Piette and Kerr.7 Clinically and economically relevant
co-morbid conditions with T2DM were identified and cate-
gorised as CC and DC.24 Initially, four mutually unique groups
were created, i.e. T2DM patients without co-morbidities; T2DM
patients with DC; T2DM patients with CC; and T2DM patients
with CC and DC, to analyse the co-morbidity profile of the
sample. Further analysis was performed on the patients with
MDD (T2DM +MDD) versus without MDD (T2DM-MDD) due to
the high prevalence of MDD in the sample.
Hospital admissions
Hospital admissions of the T2DM patients in 2014 were
extracted from the hospital case management database. The
primary diagnoses were identified by ICD10 code at the time
of the hospital admission and were classified as hospital admis-
sions for diabetes-related events (hypoglycaemia, micro- and
macrovascular events) and for non-diabetes related events.25
Hospitalisations were further categorised by same-day admis-
sions or overnight admissions. Overnight admissions included
episodes that required more than one overnight stay in hospital.
Statistical and data analysis
Data from the database were exported to a Microsoft Excel 2016
spreadsheet (Microsoft Corp, Redmond, WA, USA) and statistical
analysis was performed with Statistica 13.3 (StatSoft Inc., Tulsa,
OK, USA) and SAS 9.4 (SAS Institute, Cary, NC, USA). Continuous
variables were presented as mean and SD or median and range
and categorical variables as frequency and percentages. Com-
parisons of three independent groups were performed with
analysis of variance (ANOVA). The Bonferroni post-hoc test was
used for 2 × 2 comparisons. Categorical variables were com-
pared with chi-square test or Fisher’s exact test, as appropriate.
Where multiple comparisons between groups were performed,
the level of significance was adjusted using a Bonferroni correc-
tion, namely α/the number of comparisons. Hospitalisation costs
were calculated as the total hospital admission costs in South
African rand (ZAR) per annum and the average cost per over-
night stay. Similarly, the costs for the diabetes versus non-dia-
betes related hospital admissions were individually calculated
as the total and the average cost per annum. Average costs of
hospital admissions were presented with the SD. A significance
level was set at 0.05.
Results
Among the 46 000 registered beneficiaries (54.3% female) in the
CAMAF database, 902 T2DM patients (2%) were identified. The
co-morbidity profile of the T2DM patients is summarised in
Table 1. The mean age of this cohort was 57 ± 15 years and pre-
dominantly male (57%). In total, 85% of the identified T2DM
patients had at least one of the recorded co-morbidities. The
T2DM patients who had both a CC and a DC (41%) were signifi-
cantly older (63 ± 13.3; p < 0.0001) and had twice the rate of hos-
pitalisations (44%) compared with the other groups (p < 0.0001).
Co-morbidities of the 902 T2DM patients within the healthcare
organisation are shown in Figure 1. Patients may have one or
more CC or DC, thus representing more than one condition
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depression care for patients with acute coronary syndrome and
persistent depressive symptoms has shown promising reduction
in the rates of major adverse cardiac events.21 Therefore, we
investigated the relationship between the stated diagnoses of
T2DM and MDD, within a private managed healthcare setting,
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sample. Further analysis was performed on the patients with
MDD (T2DM +MDD) versus without MDD (T2DM-MDD) due to
the high prevalence of MDD in the sample.
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Hospital admissions of the T2DM patients in 2014 were
extracted from the hospital case management database. The
primary diagnoses were identified by ICD10 code at the time
of the hospital admission and were classified as hospital admis-
sions for diabetes-related events (hypoglycaemia, micro- and
macrovascular events) and for non-diabetes related events.25
Hospitalisations were further categorised by same-day admis-
sions or overnight admissions. Overnight admissions included
episodes that required more than one overnight stay in hospital.
Statistical and data analysis
Data from the database were exported to a Microsoft Excel 2016
spreadsheet (Microsoft Corp, Redmond, WA, USA) and statistical
analysis was performed with Statistica 13.3 (StatSoft Inc., Tulsa,
OK, USA) and SAS 9.4 (SAS Institute, Cary, NC, USA). Continuous
variables were presented as mean and SD or median and range
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used for 2 × 2 comparisons. Categorical variables were com-
pared with chi-square test or Fisher’s exact test, as appropriate.
Where multiple comparisons between groups were performed,
the level of significance was adjusted using a Bonferroni correc-
tion, namely α/the number of comparisons. Hospitalisation costs
were calculated as the total hospital admission costs in South
African rand (ZAR) per annum and the average cost per over-
night stay. Similarly, the costs for the diabetes versus non-dia-
betes related hospital admissions were individually calculated
as the total and the average cost per annum. Average costs of
hospital admissions were presented with the SD. A significance
level was set at 0.05.
Results
Among the 46 000 registered beneficiaries (54.3% female) in the
CAMAF database, 902 T2DM patients (2%) were identified. The
co-morbidity profile of the T2DM patients is summarised in
Table 1. The mean age of this cohort was 57 ± 15 years and pre-
dominantly male (57%). In total, 85% of the identified T2DM
patients had at least one of the recorded co-morbidities. The
T2DM patients who had both a CC and a DC (41%) were signifi-
cantly older (63 ± 13.3; p < 0.0001) and had twice the rate of hos-
pitalisations (44%) compared with the other groups (p < 0.0001).
Co-morbidities of the 902 T2DM patients within the healthcare
organisation are shown in Figure 1. Patients may have one or
more CC or DC, thus representing more than one condition
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within the figures. Hypertension (64%) and hyperlipidaemia
(63%) were the most prevalent CC, and MDD (17%) was the
most prevalent DC.
T2DM patients with MDD (T2DM +MDD) and
without MDD (T2DM-MDD)
Table 2 summarises the characteristics of the patients with T2DM
+MDD and T2DM-MDD. In a predominantly male sample
(Table 1), a significantly higher proportion of the female
sample (Table 2) fell into the T2DM +MDD group (p < 0.0001).
The T2DM +MDD group had a higher proportion of DC than
those without MDD.
Hospital resource utilisation of T2DM +MDD and
T2DM-MDD patients
The comparison of the hospital resource utilisation of the two
groups is presented in Table 3. There were a greater number
of T2DM +MDD patients admitted to hospital (42%) com-
pared with the T2DM-MDD (30%) group (p = 0.004) and
more patients were admitted overnight in the T2DM +MDD
group (36%) compared with the T2DM-MDD group (21%),
p = 0.0001. The overall admission rate was significantly
higher in the T2DM +MDD group (82%; p = 0.0001; with
76% being an overnight admission, p = 0.016), compared
with the T2DM-MDD group (56%) admissions (66% were
overnight stays).
Hospital admissions for diabetes and non-diabetes
related events in both groups
Table 4 compares the diabetes related admissions and costs
between the T2DM +MDD and T2DM-MDD groups. Significantly
more T2DM-MDD patients had diabetes related admissions
(27%, p = 0.018) and significantly higher cost (p = <0.001).
Figure 2 further shows that these admissions were for









with CC and DC p-value
n (%) 902 (100) 136 (15) 33 (4) 363 (40) 370 (41)
Age (years) 57 ± 14.7 44 ± 13.1 49 ± 11.2 56 ± 13.0 63 ± 13.3 < 0.0001
Male n (%) 518 (57) 82 (60) 14 (58) 233 (64) 189 (51) 0.0009
Female n (%) 384 (43) 54 (40) 19 (42) 130 (36) 181 (49)
Number of patients on
insulin n (%)
228 (25) 26 (19) 8 (24) 101 (28) 93 (25) 0.26
Number of patients
hospitalised n (%)
289 (32) 28 (21) 8 (24) 89 (25) 164 (44) < 0.0001
Figure 1: Percentage of T2DM patients with co-morbidities (a) concordant and (b) discordant with diabetes in the study.
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macrovascular complications 66% of the time, and microvascu-
lar complications in 34% of cases.
Table 5 indicates significantly higher non-diabetes related
admissions for the T2DM +MDD group (85%) compared with
the T2DM-MDD group (73%; p = 0.018) (Figure 3). The cost of
non-diabetes related admissions was similar in the two groups.
Discussion
This study reviewed the 2014 membership data of the CAMAF
iMed database and extracted 902 member records of patients
registered on the medicine management programme as
having T2DM. The co-morbidity profiles were analysed in
terms of CC and DC, yielding high rates of cardiovascular co-
morbidity and a concerning 17% of the sample presenting
with MDD, warranting further investigation into the relationship
between these conditions. Factors such as other co-morbidities,
hospital resource utilisation, diabetic versus non-diabetic com-
plications and associated costs were investigated.
Despite the predominantly female population of the CAMAF
membership, the sample comprised significantly more male
T2DM patients (57%, p = 0.0009), but the female patients were
more likely to have co-morbid MDD (63%, p = < 0.0001). It is
well known that the incidence of T2DM is slightly higher in
the male population26 and the incidence of MDD is higher in
the female T2DM population,27 as reflected in our results.
In this study 85% of the T2DM patients had at least one
additional recorded co-morbidity and were older than the
group without co-morbidities. These results are similar in the
findings of a cross-sectional analysis of 161 174 patients with
T2DM using electronic health record (EHR) data supplied by
United States providers in 2008–2012.28 Hypertension (64%)
and hyperlipidaemia (63%) were the most common CC and
are specifically targeted within the CAMAF disease management
programmes, which provides disease specific support and edu-
cation to registered members. Despite being on a private
managed care programme the number of T2DM patients
treated for the above two major contributors to CVD was
lower than the targets set by the 2017 Society for Endocrinology,
Metabolism and Diabetes of SA (SEMDSA) guideline recommen-
dations.9 The guidelines advocate that dyslipidaemia and other
CVD risk factors should be surveyed for and aggressively
managed in every patient with T2DM. The treatment gap indi-
cates that one in three T2DM patients within this managed
care organisation may need antihypertensive or lipid-lowering
intervention, as all T2DM patients should be considered at
risk.9 The prevalence rate of hypertension and hyperlipidaemia
was also lower than those reported for hypertension (82%)
and hyperlipidaemia (77%) in a study conducted by Iglay et al.
from 2014 to 2015 using EHR of a cohort of 1 389 016 American
adult T2DM patients.29 This difference could be due to the
higher prevalence of older, black and non-Hispanic patients
among the US population.
The presence of DC is an additional burden on a diabetic patient,
in terms of not only affordability to the healthcare resources, but
also the understanding of the diseases and their management.
The presence of DC has shown to be associated with diminished
care, as the illnesses have unrelated pathogenesis and disparate
Table 3: Hospital resource utilisation amongst T2DM +MDD and T2DM-











Total number of patients
hospitalised, n (%)
64 (42) 225 (30) 0.004
Number of patients
hospitalised overnight, n (%)
53 (36) 160 (21) 0.0001
Total number of hospital
admissions, n (%)
126 (82) 417 (56) <0.0001
Number of overnight
hospital admissions, n (%)
96 (76) 277 (66) 0.016
Median length of stay, days
(min, max)
4 (2, 50) 4 (2, 78) 0.67










Age (years) 60 ± 14 58 ± 15 0.13
Female, n (%) 97 (63) 287 (38) <0.0001
Number of patients on
insulin, n (%)
42 (28) 186 (25) 0.43
Concordant co-morbidities (CC):
Hypertension, n (%) 109 (71) 475 (63) 0.06
Hyperlipidaemia, n (%) 111 (73) 458 (61) 0.02
Hypothyroidism, n (%) 33 (22) 88 (12) 0.01
Coronary artery disease, n (%) 23 (15) 104 (14) 0.75
Cardiac failure, n (%) 4 (3) 14 (2) 0.44
Cardiomyopathy, n (%) 2 (1) 6 (1) 1.00
Dysrhythmia, n (%) 10 (7) 29 (4) 0.10
Stroke, n (%) 3 (2) 5 (1) 0.29
Chronic renal disease, n (%) 3 (2) 8 (1) 0.29
Glaucoma, n (%) 9 (6) 34 (5) 0.67
Deep vein thrombosis, n (%) 0 (0) 6 (1) 0.21
Discordant co-morbidities (DC):
Cancer, n (%) 15 (10) 50 (7) 0.20
Asthma, n (%) 20 (13) 46 (6) 0.002
COPD, n (%) 7 (5) 12 (2) 0.031
Epilepsy, n (%) 8 (5) 7 (1) 0.0004
Gout, n (%) 14 (9) 78 (10) 0.71
GORD, n (%) 31 (20) 51 (7) <0.0001
HIV, n (%) 2 (1) 9 (1) 1.00
Osteoarthritis n (%) 12 (8) 19 (3) 0.003
Rheumatoid arthritis, n (%) 4 (3) 10 (1) 0.049
Parkinson’s disease, n (%) 5 (3) 4 (1) 0.049
Prostate disorders, n (%) 2 (1) 17 (2) 0.40
Osteoporosis, n (%) 8 (5) 15 (2) 0.031
COPD = chronic obstructive pulmonary disease; GORD = gastro-oesophageal reflux
disorder; HIV = human immunodeficiency virus.
Table 4: Costs of diabetes-related hospitalisations amongst T2DM +








(n = 749) p-value
Diabetes-related hospital
admissions, n (%)
14/96 (15) 74/277 (27) 0.018
Total costs R455 358 R4 746 683 –
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macrovascular complications 66% of the time, and microvascu-
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admissions for the T2DM +MDD group (85%) compared with
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Parkinson’s disease, n (%) 5 (3) 4 (1) 0.049
Prostate disorders, n (%) 2 (1) 17 (2) 0.40
Osteoporosis, n (%) 8 (5) 15 (2) 0.031
COPD = chronic obstructive pulmonary disease; GORD = gastro-oesophageal reflux
disorder; HIV = human immunodeficiency virus.
Table 4: Costs of diabetes-related hospitalisations amongst T2DM +








(n = 749) p-value
Diabetes-related hospital
admissions, n (%)
14/96 (15) 74/277 (27) 0.018
Total costs R455 358 R4 746 683 –
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management plans to the T2DM management, unlike the simi-
larity of care in CC.24 In the National Health and Nutrition Exam-
ination Surveys (NHANES) conducted in the United States from
1988 to 2010, less than 50% of diabetic patients with multiple
co-morbidities achieved glycaemic, BP and LDL cholesterol
targets set by diabetes guidelines.30
The high incidence of MDD (17%) as a co-morbidity in this
sample is consistent with international statistics. A meta-analysis
of 51 331 people between 1980 and 2005 similarly showed that
MDD was significantly higher in patients with T2DM compared
with those without T2DM (17.6% vs. 9.8%).27 Data of 16 180
T2DM patients presented by a health maintenance organisation
(HMO) showed 17.9% incidence of MDD.31 Depressive symp-
toms in individuals with diabetes have shown to be associated
with poor glycaemic control and increased risk of micro- and
macrovascular complications.32,33
Certain antidepressants i.e. paroxetine, mirtazapine and venla-
faxine, have been shown to be associated with increased lipid
levels and could possibly contribute to hyperlipidaemia in the
group of patients treated for MDD.34,35 The clinical parameters,
i.e. lipid levels, BP and blood glucose, of the T2DM patients
with and without MDD were not evaluated at this stage.
Further studies will require evaluation of the clinical parameters
of this cohort of T2DM patients. In this study, hyperlipidaemia
was a generic classification on the system as a code and did
not specify the type of hyperlipidaemia.
The presence of DC may draw resources away from other
disease management and could compromise diabetes self-care
in patients with pre-existing CC.24 The T2DM +MDD group indi-
cated higher rates of both CC and DC than their non-MDD
counterparts. To support our findings Von Korff and colleagues
have revealed that childhood adversity and depression occur-
ring in adolescence to early adulthood were independent risk
factors for development later of a range of medical disorders,
including diabetes, CAD, asthma, osteoarthritis, epilepsy and
hypertension.36
Conditions such as MDD, arthritis and asthma pose significant
barriers to lifestyle changes and regimen adherence in
patients with T2DM.37 The prevalence of gastro-oesophageal
reflux disorder (GORD) was significantly higher in patients
with MDD in a cross-sectional study using the National
Health Insurance Research Database in Taiwan during 2005;
the study subjects included 4 790 patients with MDD and
728 749 people in the general population.38 Likewise in our
study, a significantly higher number of T2DM patients with
MDD had co-morbid GORD compared with the group of
T2DM without MDD.
A greater proportion of the T2DM +MDD patients (42%) were
hospitalised compared with those without MDD (30%) during
2014. The increased rate of hospital admissions could be due
to non-adherence to diabetic management, which leads to
increased rates of diabetic complications such as ischaemic
heart disease, peripheral vascular disease and admissions as
reported in the Canadian study.39 In our study, the diabetic
patients who were being treated for MDD experienced more
microvascular (polyneuropathy, macular degeneration) compli-
cations than those with diabetes alone. The presence of MDD
might compromise diabetes care possibly because of over- or
under-treatment, competing for time, attention or limited
resources. This suggests the need for integrated care
Figure 2: Diabetes-related hospital events in T2DM +MDD and T2DM-MDD.
Figure 3: Non-diabetes related hospital events in T2DM +MDD and
T2DM-MDD.
Table 5: Costs of non-diabetes related hospitalisations amongst T2DM +
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Non-diabetes related
admissions, n (%)
82/96 (85) 203/277 (73) 0.018
Total costs R4 150 932 R10 018 689 –
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coordination within the healthcare system to improve diabetes
care among patients with MDD.
In addition, the results of this study also showed that in T2DM
patients with MDD the rate of hospitalisation for non-diabetes
related complications was much higher than for those without
MDD. In a systematic review between the years 1995 and 2008
the studies focused mainly on outcomes, such as the changes
in depressive symptoms and HbA1c.40 Reduction of diabetes
and non-diabetes related complications by active surveillance
of diabetes and depression can improve and benefit this
group of diabetic patients. Within CAMAF, DC are not looked
at in the management of T2DM patients, as the focus is mainly
targeting the CC, i.e. hypertension and hyperlipidaemia.
There was significantly higher hospitalisation cost for T2DM-MDD,
though the LOS in hospital was similar between the T2DM+MDD
and T2DM-MDD groups. The increased hospital costs could be
attributed to the macrovascular complications of T2DM without
MDD. Studies showed that hospitalisation costs associated with
major CAD, stroke and heart failure are significantly higher than
hospitalisations for non-major cardiovascular outcomes.4
In our group of T2DM+MDD, the patients were less likely to be
hospitalised for macrovascular complications than those
without MDD, which is contrary to what is stated in the literature
where the presence of MDD in T2DM patients may compromise
T2DM care. However, the T2DM-MDD were more likely to be hos-
pitalised for macrovascular complications with significantly higher
cost per admission. This suggests that the CAMAF medicine and
the mental wellness programmesmay bemore effective in mana-
ging T2DM and MDD, and that the patients are more aware of
their health status and were compliant with their treatment for
T2DM and MDD. However, as we have very little information on
the behaviour of the T2DM patients with and without MDD
within CAMAF, future studies will be required to investigate the
difference in outcomes of these groups of T2DM patients.
Patients registered for MDD on the chronic programme are
treated for depressive symptoms with psychotherapy and anti-
depressants. This suggests that if the underlying MDD in
T2DM patients is identified and treated, it would result in
better T2DM outcomes, i.e. less hospitalisation for diabetic-
related events or better diabetes management. The American
Heart Association Science advisory committee, endorsed by
the American Psychiatric Association, recommends that if the
underlying MDD in CVD patients is identified and treated, the
cardiovascular outcome is much improved.41 Evidence exists
for improved outcomes and lower financial burden by managing
combined co-morbid conditions such as diabetes and hyperten-
sion; it was demonstrated in the UKPDS study17 that tight BP
control in patients with hypertension and T2DM reduced the
risk of diabetes-related complications and deaths. Similarly,
improved outcomes were demonstrated in a randomised
control trial done on the integration management of T2DM
and co-morbid MDD treatment to improve medication adher-
ence at primary care level.42 Due to the higher incidence of
MDD in patients with T2DM (17%), more active surveillance of
the T2DM patients for depressive symptoms is warranted for
the early identification and treatment of MDD, possibly improv-
ing the CVD outcomes.
There is a need for additional research into the relationships
between discordant co-morbid conditions such as MDD in
T2DM patients to identify strategies to improve clinical
outcomes. Further focus on the co-morbid status of other DC-
related conditions would shed light on the pattern and clusters
of multiple conditions that the T2DM patients are burdened with
and associated poor patient outcomes. Healthcare organisations
need to emphasise integrated multiple disease management in
T2DM and MDD patients to lower the disease burden and
improve outcomes.
Conclusion
Our results showed that in this cohort of 902 T2DM patients the
incidence of MDD was 17%, a major discordant co-morbidity
warranting deeper investigation into the relationship between
T2DM and MDD.
Hospital resource utilisation of overnight admissions was higher
among the patients with MDD compared with those without
MDD. There was a greater number of admissions for non-dia-
betes related hospital events in the T2DM +MDD group com-
pared with the T2DM-MDD group.
Active surveillance of T2DM patients is a recommendation for
the future, where MDD is identified and treated to lessen the
disease burden and reduce micro- and macrovascular compli-
cations. Future research needs to look at hospital and resource
utilisation in T2DM patients with the added burden of MDD
and to elucidate the healthcare needs of those patients.
A prospective study is being conducted on T2DM patients with
and without MDD to identify factors associated with diabetes
control such as blood glucose, BP and lipid profiles, and to
compare the total healthcare costs.
Limitations
The administrative claims database has limitations regarding accu-
racy of diagnostic coding, billing practices and incomplete records.
As the T2DM patients were from a private managed care organis-
ation, their healthcare utilisation and costs might not represent
those of uninsured patients or those managed in a public health-
care sector. The outcomes of this study are thus limited to the pri-
vately managed healthcare environment in South Africa.
The study was not statistically powered to perform amultivariate
analysis to determine the contributions to number and cost
admissions adjusting for individual co-morbidities.
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coordination within the healthcare system to improve diabetes
care among patients with MDD.
In addition, the results of this study also showed that in T2DM
patients with MDD the rate of hospitalisation for non-diabetes
related complications was much higher than for those without
MDD. In a systematic review between the years 1995 and 2008
the studies focused mainly on outcomes, such as the changes
in depressive symptoms and HbA1c.40 Reduction of diabetes
and non-diabetes related complications by active surveillance
of diabetes and depression can improve and benefit this
group of diabetic patients. Within CAMAF, DC are not looked
at in the management of T2DM patients, as the focus is mainly
targeting the CC, i.e. hypertension and hyperlipidaemia.
There was significantly higher hospitalisation cost for T2DM-MDD,
though the LOS in hospital was similar between the T2DM+MDD
and T2DM-MDD groups. The increased hospital costs could be
attributed to the macrovascular complications of T2DM without
MDD. Studies showed that hospitalisation costs associated with
major CAD, stroke and heart failure are significantly higher than
hospitalisations for non-major cardiovascular outcomes.4
In our group of T2DM+MDD, the patients were less likely to be
hospitalised for macrovascular complications than those
without MDD, which is contrary to what is stated in the literature
where the presence of MDD in T2DM patients may compromise
T2DM care. However, the T2DM-MDD were more likely to be hos-
pitalised for macrovascular complications with significantly higher
cost per admission. This suggests that the CAMAF medicine and
the mental wellness programmesmay bemore effective in mana-
ging T2DM and MDD, and that the patients are more aware of
their health status and were compliant with their treatment for
T2DM and MDD. However, as we have very little information on
the behaviour of the T2DM patients with and without MDD
within CAMAF, future studies will be required to investigate the
difference in outcomes of these groups of T2DM patients.
Patients registered for MDD on the chronic programme are
treated for depressive symptoms with psychotherapy and anti-
depressants. This suggests that if the underlying MDD in
T2DM patients is identified and treated, it would result in
better T2DM outcomes, i.e. less hospitalisation for diabetic-
related events or better diabetes management. The American
Heart Association Science advisory committee, endorsed by
the American Psychiatric Association, recommends that if the
underlying MDD in CVD patients is identified and treated, the
cardiovascular outcome is much improved.41 Evidence exists
for improved outcomes and lower financial burden by managing
combined co-morbid conditions such as diabetes and hyperten-
sion; it was demonstrated in the UKPDS study17 that tight BP
control in patients with hypertension and T2DM reduced the
risk of diabetes-related complications and deaths. Similarly,
improved outcomes were demonstrated in a randomised
control trial done on the integration management of T2DM
and co-morbid MDD treatment to improve medication adher-
ence at primary care level.42 Due to the higher incidence of
MDD in patients with T2DM (17%), more active surveillance of
the T2DM patients for depressive symptoms is warranted for
the early identification and treatment of MDD, possibly improv-
ing the CVD outcomes.
There is a need for additional research into the relationships
between discordant co-morbid conditions such as MDD in
T2DM patients to identify strategies to improve clinical
outcomes. Further focus on the co-morbid status of other DC-
related conditions would shed light on the pattern and clusters
of multiple conditions that the T2DM patients are burdened with
and associated poor patient outcomes. Healthcare organisations
need to emphasise integrated multiple disease management in
T2DM and MDD patients to lower the disease burden and
improve outcomes.
Conclusion
Our results showed that in this cohort of 902 T2DM patients the
incidence of MDD was 17%, a major discordant co-morbidity
warranting deeper investigation into the relationship between
T2DM and MDD.
Hospital resource utilisation of overnight admissions was higher
among the patients with MDD compared with those without
MDD. There was a greater number of admissions for non-dia-
betes related hospital events in the T2DM +MDD group com-
pared with the T2DM-MDD group.
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the future, where MDD is identified and treated to lessen the
disease burden and reduce micro- and macrovascular compli-
cations. Future research needs to look at hospital and resource
utilisation in T2DM patients with the added burden of MDD
and to elucidate the healthcare needs of those patients.
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control such as blood glucose, BP and lipid profiles, and to
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